Campagnoli Thalmon R, Kim Sung Soo, Smiddy William E, Gedde Steve J, Budenz Donald L, Parrish Richard K, Palmberg Paul F, Feuer William, Shi Wei
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, South Korea.
Int J Ophthalmol. 2015 Oct 18;8(5):916-21. doi: 10.3980/j.issn.2222-3959.2015.05.11. eCollection 2015.
To evaluate outcomes of combined pars plana vitrectomy and Baerveldt glaucoma implant (PPV-BGI) placement for refractory glaucoma.
The medical records of 92 eyes (89 patients) that underwent PPV-BGI were retrospectively reviewed, including 43 eyes with neovascular glaucoma (NVG) and 49 eyes with other types of glaucoma (non-NVG).
Outcome measures were visual acuity (VA), intraocular pressure (IOP), glaucoma medical therapy, complications, and success [VA>hand motions (HM), IOP≥6 mm Hg and ≤21 mm Hg, no subsequent glaucoma surgery]. Cumulative success rates for the non-NVG group and NVG group were 79% and 40% at 1y, respectively (P=0.038). No difference in the rates of surgical success were found between pars plana and anterior chamber tube placement. Preoperative IOP (mean±SD) was 30.3±11.7 mm Hg in the Non-NVG group and 40.0±10.6 mm Hg in the NVG group, and IOP was reduced to 15±9.5 mm Hg in the non-NVG group and 15±10.5 mm Hg in the NVG at 1y. Number of glaucoma medications (mean±SD) decreased from 2.7±1.3 in the non-NVG group and 2.8±1.3 in the NVG group preoperatively to 0.76±1.18 in the non-NVG group and 0.51±1.00 in the NVG group at 1y. Improvement in VA of ≥2 Snellen lines was observed in 25 (27%) eyes, although only 33% of non-NVG eyes and 2.3% of NVG eyes maintained VA better than 20/200 at 1y. Nonclearing vitreous hemorrhage was the most common postoperative complication occurring in 16 (17%) eyes, and postoperative suprachoroidal hemorrhages developed in 5 (5.4%) eyes.
PPV-BGI is a viable surgical option for eyes with refractory glaucoma, but visual outcomes are frequently poor because of ocular comorbidities, especially in eyes with NVG. The location of tube placement does not influence surgical outcome and should be left to the discretion of the surgeon.
评估玻璃体切割联合Baerveldt青光眼引流物植入术(PPV - BGI)治疗难治性青光眼的效果。
回顾性分析92只眼(89例患者)接受PPV - BGI手术的病历,其中43只眼为新生血管性青光眼(NVG),49只眼为其他类型青光眼(非NVG)。
观察指标包括视力(VA)、眼压(IOP)、青光眼药物治疗、并发症及手术成功情况[VA>手动(HM)、IOP≥6 mmHg且≤21 mmHg、无需后续青光眼手术]。非NVG组和NVG组1年时的累积成功率分别为79%和40%(P = 0.038)。玻璃体平坦部和前房引流管植入的手术成功率无差异。非NVG组术前眼压(均值±标准差)为30.3±11.7 mmHg,NVG组为40.0±10.6 mmHg;1年时非NVG组眼压降至15±9.5 mmHg,NVG组降至15±10.5 mmHg。青光眼药物使用数量(均值±标准差)从非NVG组术前的2.7±1.3种和NVG组术前的2.8±1.3种,降至非NVG组1年时的0.76±1.18种和NVG组1年时的0.51±1.00种。1年时,25只眼(27%)视力提高≥2行Snellen视力表,尽管只有33%的非NVG眼和2.3%的NVG眼1年时视力维持在20/200以上。非清除性玻璃体积血是最常见的术后并发症,发生于16只眼(17%),5只眼(5.4%)发生术后脉络膜上腔出血。
PPV - BGI是难治性青光眼可行的手术选择,但由于眼部合并症,尤其是NVG患者,视力预后通常较差。引流管植入位置不影响手术效果,应由手术医生酌情决定。